GENI
Genius Sports Limited
GENI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
NBIS
Nebius Group N.V.
There isn't enough reported data to score NBIS yet.
GENI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
GENI's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
NBIS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Healthy |
NBIS's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
GENI PE Valuation
GENI has no meaningful PE right now: it lost money over the past year.
NBIS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 68x | $22.45 | -83% |
| Fair | 114x | $37.67 | -71% |
| Current | 390x | $129 | — |
| Expensive | 666x | $220 | +71% |
Historical ranges are pointers, not guarantees.
NBIS's PE is 390x, but its earnings don't support one, so it isn't a reliable read right now.
GENI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect GENI's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NBIS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NBIS has the edge over GENI on the outlook, with more favorable earnings and profitability expectations.
GENI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.68 | -$0.37 |
| Q1 2026 | -$0.61 | -$0.42 |
| Q4 2025 | -$0.43 | -$0.16 |
| Q3 2025 | -$0.47 | -$0.15 |
| Q2 2025 | -$0.31 | +$0.12 |
| Q1 2025 | -$0.19 | +$0.20 |
| Q4 2024 | -$0.27 | +$0.13 |
| Q3 2024 | -$0.32 | +$0.54 |
GENI is still losing money, but far less than before: $0.68 per share over the past year, against $3.94 at its worst in early 2022.
NBIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.33 | +$2.61 |
| Q4 2024 | -$2.28 | -456% |
| Q4 2023 | $0.64 | -36% |
| Q4 2022 | $1.00 | +$1.49 |
| Q4 2021 | -$0.49 | -156% |
| Q4 2020 | $0.87 | +89% |
| Q4 2019 | $0.46 | -73% |
| Q4 2018 | $1.71 | +434% |
NBIS has the edge over GENI in the latest year-over-year earnings comparison.
GENI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $195.5M | +65% |
| Q1 2026 | $188M | +31% |
| Q4 2025 | $240.5M | +37% |
| Q3 2025 | $166.3M | +38% |
| Q2 2025 | $118.7M | +24% |
| Q1 2025 | $144M | +20% |
| Q4 2024 | $175.5M | +38% |
| Q3 2024 | $120.2M | +18% |
GENI has the edge over NBIS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -14% | +54 points |
| Q1 2026 | -16% | -1.6 points |
| Q4 2025 | -8.4% | -4.3 points |
| Q3 2025 | -14% | -8.8 points |
| Q2 2025 | -68% | -46 points |
| Q1 2025 | -14% | +6.1 points |
| Q4 2024 | -4.1% | +23 points |
| Q3 2024 | -5% | +3.7 points |
GENI's operating margin was −14% last quarter, up 54 points from the same quarter a year ago.
NBIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $9.7B | +53% |
| Q4 2022 | $6.3B | +46% |
| Q4 2021 | $4.3B | +63% |
| Q4 2020 | $2.6B | +24% |
| Q4 2019 | $2.1B | +37% |
| Q4 2018 | $1.5B | +36% |
| Q4 2017 | $1.1B | +24% |
| Q4 2016 | $917M | +27% |
NBIS's revenue is growing: $530M last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -115% | -112 points |
| Q4 2023 | 3.6% | -11 points |
| Q4 2022 | 2.5% | -14 points |
| Q4 2021 | -3.7% | -18 points |
| Q4 2020 | 7.4% | -9.5 points |
| Q4 2019 | 14% | -2 points |
| Q4 2018 | 16% | -14 points |
| Q4 2017 | 14% | -19 points |
NBIS's operating margin was −115% last quarter, down 123 points from the same quarter a year ago, near the bottom of its range since 2011.
GENI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$87M | -$67.8M |
| Q1 2026 | -$68.2M | -$20M |
| Q4 2025 | $69.6M | -0.4% |
| Q3 2025 | $19.1M | +$41.8M |
| Q2 2025 | -$19.2M | -$16.5M |
| Q1 2025 | -$48.3M | -$21.3M |
| Q4 2024 | $69.9M | +559% |
| Q3 2024 | -$22.7M | -7493% |
GENI has burned cash in most quarters: −$66M over the past year, against −$20M the year before.
NBIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.7B | -$3.1B |
| Q4 2024 | -$562.1M | -$316.2M |
| Q4 2023 | -$245.9M | -$138.9M |
| Q4 2022 | -$107M | +$319.7M |
| Q4 2021 | -$426.7M | -539% |
| Q4 2020 | $97.3M | -66% |
| Q4 2019 | $287.9M | +$289.2M |
| Q4 2018 | -$1.3M | -101% |
NBIS has burned cash in six of the last eight quarters: −$4.6B over the past year, against −$43M the year before.
GENI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +9.5M shares |
| 1 year | +10% | +25.7M shares |
| 3 years | +34% | +70.4M shares |
| 5 years | +85% | +128M shares |
| Available history | +56% | +100M shares |
GENI has 279M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GENI hasn't bought back shares in the past year.
NBIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -33.3M shares |
| 1 year | -32% | -115M shares |
| 3 years | -26% | -86.9M shares |
NBIS has the edge over GENI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | $10M |
| Q4 2021 | $84.1M |
| Q4 2020 | $122.8M |
| Q4 2019 | $17.2M |
| Q4 2018 | $121.8M |
| Q4 2014 | $101.7M |
| Q4 2013 | $102.9M |
GENI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -12.5x | Net Cash |
| Q4 2024 | -6.3x | Net Cash |
| Q1 2024 | -7.5x | Net Cash |
| Q4 2023 | -15.2x | Net Cash |
| Q1 2021 | 4.3x | High |
| Q4 2020 | 5.5x | High |
| Q3 2020 | 9.1x | High |
GENI has more cash than debt.
NBIS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 0.7x | Very low |
| Q4 2022 | -0.7x | Net Cash |
NBIS's net debt is less than a year of its operating earnings (EBITDA).
GENI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 23.4 | Neutral |
GENI's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
NBIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 8.3 | Oversold |
NBIS's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
GENI PE vs Communication Services Sector
GENI has no meaningful PE right now: it lost money over the past year.
NBIS PE vs Communication Services Sector
| Metric | NBIS | Sector median | Relative |
|---|---|---|---|
| PE | 390x | 16x | 2,264% above |
| PE % | 62 | 24 | 38 pts above |
NBIS is trading at 390x earnings, a 2264% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
GENI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.28 | 2.9% below |
| 20 week MA | $6.73 | 9.4% below |
| 50 week MA | $6.77 | 9.9% below |
| 100 week MA | $8.60 | 29% below |
| 200 week MA | $7.35 | 17% below |
NBIS has stronger trend alignment. GENI is above 0 of 5 weekly averages versus NBIS above 1 of 4.
NBIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $179.7 | 28% below |
| 20 week MA | $199.9 | 36% below |
| 50 week MA | $163.5 | 21% below |
| 100 week MA | $110.0 | 17% above |
NBIS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 17% above its 100-week average.
GENI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $16.6 | +68% |
| 2021 | $16.6 | $7.61 | -54% |
| 2022 | $7.61 | $3.27 | -57% |
| 2023 | $3.27 | $6.18 | +89% |
| 2024 | $6.18 | $8.75 | +42% |
| 2025 | $8.75 | $10.9 | +24% |
| 2026 YTD | $10.9 | $6.10 | -44% |
GENI is down 44% so far in 2026, after finishing higher in four of the previous six years.
NBIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.6 | $27.3 | +40% |
| 2025 | $27.3 | $87.6 | +221% |
| 2026 YTD | $87.6 | $128.6 | +47% |
NBIS has the edge over GENI on returns for 2026, with the stronger performance.